Los Angeles Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Los Angeles Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$836K	Buy	601,308 +571,701	+1,931%	+$786K	﹤0.01%	730
2025 Q4	$62.2K	Hold	29,607	–	–	﹤0.01%	1538
2025 Q3	$80.8K	Buy	29,607 +2,864	+11%	+$9.53K	﹤0.01%	1324
2025 Q2	$97.3K	Buy	26,743 +70	+0.3%	+$192	﹤0.01%	1254
2025 Q1	$51.2K	Buy	+26,673	New	+$54.4K	﹤0.01%	1075
2020 Q4	–	Sell	-26,550	Closed	-$67K	–	1505
2020 Q3	$67K	Buy	26,550 +12,310	+86%	+$108K	﹤0.01%	1423
2020 Q2	$193K	Buy	+14,240	New	+$147K	﹤0.01%	1402
2018 Q4	–	Sell	-33,655	Closed	-$297K	–	1262
2018 Q3	$297K	Sell	33,655 -136,070	-80%	-$1.22M	﹤0.01%	1226
2018 Q2	$1.69M	Buy	169,725 +103,920	+158%	+$1.04M	0.01%	740
2018 Q1	$627K	Buy	65,805 +7,925	+14%	+$111K	﹤0.01%	964
2017 Q4	$861K	Buy	57,880 +4,840	+9%	+$80.3K	﹤0.01%	891
2017 Q3	$1.04M	Buy	+53,040	New	+$815K	0.01%	807

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Los Angeles Capital Management's AKBA Position: Q1 2026 in Review

Los Angeles Capital Management increased its Akebia Therapeutics (AKBA) stake by 1,931% in Q1 2026, buying an estimated $786K and bringing the position to 601,308 shares worth $836K. The position accounts for ﹤0.01% of the portfolio, ranked #730.

Los Angeles Capital Management first reported a position in AKBA in Q3 2017 and has held it in 12 quarters since. The position peaked at $1.69M in Q2 2018. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Los Angeles Capital Management held 601,308 shares of Akebia Therapeutics worth $836K as of Q1 2026.
Los Angeles Capital Management bought 571,701 Akebia Therapeutics shares in Q1 2026, an estimated $786K.
Akebia Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #730 holding.
Los Angeles Capital Management first reported a position in Akebia Therapeutics in Q3 2017 and has held it in 12 quarters since.
Los Angeles Capital Management's Akebia Therapeutics position peaked at $1.69M in Q2 2018.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.